Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | ME3 | Q16798 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799776 | 0.83 | ABL1 (0.51) | TRPV1ME3ABL1MALT1MAPT | |
| SCHEMBL5799454 | 0.83 | ABL1 (0.48) | TRPV1ME3ABL1RXFP1LMNA | |
| SCHEMBL5802998 | 0.80 | ABL1 (0.48) | TRPV1ME3ABL1MALT1RXFP1 | |
| SCHEMBL5799778 | 0.80 | TRPV1 (0.49) | TRPV1ME3ABL1RXFP1LMNA | |
| SCHEMBL5801872 | 0.76 | POLB (0.47) | POLBMALT1MAPTRXFP1TP53 | |
| SCHEMBL6072140 | 0.76 | HSD17B10 (0.56) | ABL1MAPTLMNA | |
| SCHEMBL26131257 | 0.75 | ROCK2 (0.48) | TRPV1ME3MALT1EPHX2 | |
| SCHEMBL5799831 | 0.74 | NOTUM (0.55) | LMNA | |
| SCHEMBL5802659 | 0.73 | TRPV1 (0.76) | TRPV1ME3MALT1MAPTTP53 | |
| SCHEMBL5802548 | 0.72 | TRPV1 (0.68) | TRPV1ME3POLBMALT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | TRPV1 2/4885ME3 2330/4885POLB 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.